戴维医疗
(300314)
| 流通市值：20.47亿 | | | 总市值：31.13亿 |
| 流通股本：1.89亿 | | | 总股本：2.88亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 402,925,721.56 | 265,824,458.42 | 155,328,964.53 | 618,298,238.74 |
| 营业收入 | 402,925,721.56 | 265,824,458.42 | 155,328,964.53 | 618,298,238.74 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 335,740,052.47 | 215,490,046.49 | 108,971,100.08 | 471,574,505.83 |
| 营业成本 | 174,144,094.74 | 111,091,872.38 | 64,421,182.5 | 258,478,134.3 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 3,844,503.01 | 3,190,684.43 | 1,035,494.63 | 8,853,445.6 |
| 销售费用 | 78,471,072.93 | 52,683,236.4 | 22,670,944.08 | 121,920,460.25 |
| 管理费用 | 45,909,038.37 | 29,536,942.22 | 13,296,577.44 | 54,206,836.26 |
| 研发费用 | 38,881,143.78 | 25,011,237.72 | 10,287,345.11 | 48,059,212.59 |
| 财务费用 | -5,509,800.36 | -6,023,926.66 | -2,740,443.68 | -19,943,583.17 |
| 其中:利息费用 | 365,287.52 | 254,170.94 | 132,751.17 | 598,807.42 |
| 其中:利息收入 | 7,504,563.44 | 5,754,090.81 | 2,802,839.84 | 14,540,986.45 |
| 加:公允价值变动收益 | - | - | - | 263,863.02 |
| 加:投资收益 | -873,836.79 | -3,132,061.27 | -2,554,623.67 | 11,328,629.48 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 4,578.89 | -27,356.62 | -43,673.56 | -228,115.57 |
| 资产减值损失(新) | - | - | - | -2,690,137.06 |
| 信用减值损失(新) | -1,917,759.3 | -1,033,274.02 | -652,079.94 | -472,598.94 |
| 其他收益 | 7,517,469.38 | 6,757,919.06 | 1,381,449.45 | 16,439,286.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 71,916,121.27 | 52,899,639.08 | 44,488,936.73 | 171,364,659.96 |
| 加:营业外收入 | 196,909.73 | 78,133.43 | 82,130.68 | 155,550.22 |
| 减:营业外支出 | 226,921.15 | 180,050.76 | 140,875.84 | 5,295,485.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 71,886,109.85 | 52,797,721.75 | 44,430,191.57 | 166,224,724.77 |
| 减:所得税费用 | 8,578,237.79 | 6,271,576.39 | 6,322,962.81 | 18,613,813.26 |
| 六、净利润 | 63,307,872.06 | 46,526,145.36 | 38,107,228.76 | 147,610,911.51 |
| 持续经营净利润 | 63,307,872.06 | 46,526,145.36 | 38,107,228.76 | 147,610,911.51 |
| 归属于母公司股东的净利润 | 63,307,872.06 | 46,526,145.36 | 38,107,228.76 | 147,610,911.51 |
| (一)基本每股收益 | 0.22 | 0.16 | 0.13 | 0.51 |
| (二)稀释每股收益 | 0.22 | 0.16 | 0.13 | 0.51 |
| 八、其他综合收益 | 306,790.36 | -171,801.45 | - | 0 |
| 归属于母公司股东的其他综合收益 | 306,790.36 | -171,801.45 | - | 0 |
| 九、综合收益总额 | 63,614,662.42 | 46,354,343.91 | 38,107,228.76 | 147,610,911.51 |
| 归属于母公司股东的综合收益总额 | 63,614,662.42 | 46,354,343.91 | 38,107,228.76 | 147,610,911.51 |
| 归属于少数股东的综合收益总额 | - | - | - | 0 |
| 公告日期 | 2024-10-23 | 2024-08-20 | 2024-04-20 | 2024-04-09 |
| 审计意见(境内) | | | | 标准无保留意见 |